Systemic effects of topical ophthalmic β-adrenoceptor antagonists

Clinical and Experimental Ophthalmology

Volumn 27, Issue 1, 1999, Pages 57-64

  Rait, Julian L ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE   (Australia)

Author keywords

Asthma; Beta blockers; Betaxolol; Glaucoma; Timolol

Indexed keywords

EID: 17944379207     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J. Pharmacol. Exp. Ther. 1963; 140: 308-16.
2. Philips CL, Howitt G, Rowlands DJ. Propranolol, an ocular hypotensive agent. Br. J. Ophthalmol. 1967; 51: 222-6.
3. Goodman LS, Gilman A. The Pharmacologic Basis of Therapeutics. New York: Macmillan, 1985.
4. Fraunfelder FT, Meyer SM. Sexual dysfunction secondary to topical ophthalmic timolol. JAMA 1985; 253: 3092-3 (Letter).
5. Orlando RG. Clinical depression associated with betaxolol. Am. J. Ophthalmol. 1986; 102: 275.
6. Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical beta-blocker therapy and central nervous system side effects. A preliminary study comparing timolol and betaxolol. Arch. Ophthalmol. 1988; 106: 908-11.
7. Liddell NE, Paterson CA. Systemic side effects of ocular beta adrenergic blocking agents. CVR & R 1989; 27-30.
8. Shore JH, Fraunfelder FT, Meyer SM. Psychiatric side effects from topical ocular timolol, a beta adrenergic blocker. J. Clin. Psychopharmacol. 1987; 7: 264-7.
9. Levy B, Wilkenfeld BE. Selective interactions with beta adrenergic receptors. Fed. Proc. Fed. Am. Soc. Exp. Biol. 1970; 29: 1362-4.
10. Safar M. Ageing and its effects on the cardiovascular system. Drugs 1990; 39 (Suppl. 1): 1-8.
11. Freedman SF, Freedman NJ, Shields MB et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am. J. Ophthalmol. 1993; 116: 600-11.
12. Vuori ML, Ali-Meikkilä T, Kaila T, Lisalo E, Saari M. Beta-1 and beta-2 antagonist activity of topically applied betaxolol and timolol in the systemic circulation. Acta Ophthalmol. 1993; 71: 682-5.
13. Weinstein P. Receptor paralysing agents applied in the treatment of glaucoma simplex. Int. Z. Klin. Pharm. Ther. Toxikol. 1969; 2: 374-5.
14. Ghall RA, Robson RD, Share NN. Timolol maleate: A new beta adrenergic receptor blocking agent. Arch. Int. Pharmodyn. Ther. 1975; 213: 251-63.
15. DeSantis L, Polansky JR, Bruce L. Relative differences in beta receptor activity between the cardioselective beta blocker, betaxolol and nonselective beta blockers. New Trends Ophthalmol. 1987; 2: 124-30.